The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...
The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...
In urology we are encountering an ageing and more comorbid population, including a group of patients with chronic kidney disease (CKD). In this retrospective study, a group from the Cleveland Clinic present the extended follow-up of patients with and without...
Movember has launched the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year. The leading...
This large-scale meta-analysis, incorporating studies from several population-based studies, evaluated the association between inflammatory bowel disease (IBC) and prostate cancer (Pca). Emerging evidence has suggested that IBD is a risk factor for extra-intestinal malignancies which may be due to an...
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...
In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...
This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...
A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men. Funded by Prostate Cancer UK in partnership with Movember, the PROFILE study will look...
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...